What happened: On December 12, 2025, the U.S. District Court for the District of Columbia granted summary judgment for the federal government in Frech v. U.S. Department of Health and Human Services, upholding both the research-misconduct findings and the three-year debarment issued by HHS’s Office of Research Integrity (ORI) against researcher Ivana Frech (formerly Ivana De Domenico). The ruling closes out Frech’s district-court challenge to a finding that has been in progress, in one form or another, since 2011.
The ORI findings
Frech was a researcher in the University of Utah’s Department of Internal Medicine, School of Medicine, working on NIH-funded studies of cellular iron regulation, when questions about her image data first surfaced. ORI’s eventual finding, made effective August 21, 2023, concluded that Frech engaged in research misconduct by falsifying and/or fabricating western blot and autoradiogram images — eight images across three publications supported by Public Health Service (PHS) funding, including NIH grants from NIDDK, NIGMS, NIAID, and NHLBI. Two of the three affected papers, both published in Cell Metabolism, were retracted in 2012, years before ORI’s own finding was finalized; HHS also directed a notice to Developmental Cell regarding the third.
Based on that finding, HHS’s Deputy Assistant Secretary for Acquisitions — the agency’s debarring official — imposed a three-year debarment barring Frech from covered federal transactions and from serving on PHS advisory committees, peer-review panels, or in consulting roles, running from August 21, 2023 through August 2026.
The lawsuit and the court’s ruling
Frech sued HHS in 2023, arguing that ORI’s misconduct findings and the resulting debarment were arbitrary, capricious, an abuse of discretion, and unsupported by substantial evidence. The case, assigned to Judge Christopher R. Cooper in the U.S. District Court for the District of Columbia, turned on whether the agency’s administrative record supported its conclusions under the deferential standard courts apply to federal agency action.
On December 12, 2025, Judge Cooper granted the government’s motion for summary judgment, finding no genuine dispute of material fact and that HHS had “articulated a rational connection between the facts found and the choice made.” The ruling upholds both the underlying misconduct findings and the debarment as issued. Notably, Cooper’s opinion did not simply rubber-stamp the agency: he wrote that the court “does not doubt that Dr. Frech may make meaningful contributions to the scientific community in the future,” and he declined to endorse the roughly decade-long gap between the initial allegations and ORI’s finalized finding — without treating that delay as grounds to overturn the agency’s decision.
What the debarment means in practice
A PHS/ORI research-misconduct finding and a debarment are two linked but distinct administrative actions. The misconduct finding is ORI’s determination, following an institutional and then federal review, that specific conduct meets the regulatory definition of fabrication, falsification, or plagiarism. The debarment is a separate action by an HHS debarring official, using that finding as its basis, that excludes the individual from participating in covered transactions — direct federal grants and contracts, and often subawards and consulting arrangements tied to federal funding — for a defined period. Institutions and sponsors typically check debarment status through the federal System for Award Management (SAM.gov) before making funding or hiring decisions involving PHS-supported research.
Because the district court’s ruling upholds both pieces — the finding and the debarment — the case stands, for now, as a closed, adjudicated matter rather than an open or unresolved allegation. The debarment itself, unless further appealed, runs its course through August 2026.
Why this case matters for research-integrity offices
Frech v. HHS is one of a small number of ORI debarment decisions to be tested, and upheld, in federal court, which gives research-integrity officers and grants administrators a rare judicial data point on how much deference courts extend to ORI’s process. Two aspects are likely to be cited in future institutional guidance and in similar litigation:
- The “arbitrary and capricious” bar is high. The court’s summary-judgment ruling confirms that ORI’s administrative record, including the reasoning connecting its factual findings to the debarment decision, can satisfy judicial review even where the underlying investigation took many years.
- Long investigation timelines don’t automatically undermine a finding. The roughly decade-long span between the initial 2011 allegations and the 2023 finding drew explicit judicial comment but was not treated as an independent basis to set the debarment aside — a point relevant to institutions and respondents alike in cases where inquiries and investigations run long.
For a step-by-step look at how a federal misconduct case reaches this stage, see How a Research Misconduct Investigation Actually Works, and for the range of sanctions ORI findings can trigger, see The Consequences of Research Misconduct: Career, Funding, and Legal Outcomes.
Case timeline
- 2011: Questions about image data in Frech’s (then De Domenico’s) published work first surface.
- 2012: Two of the three papers later cited in ORI’s finding, both in Cell Metabolism, are retracted.
- ~2013: Frech’s employment at the University of Utah ends, roughly a decade before ORI’s finding is finalized.
- August 21, 2023: ORI’s misconduct finding and HHS’s three-year debarment take effect (Federal Register notice published September 5, 2023).
- 2023: Frech files suit against HHS in the U.S. District Court for the District of Columbia.
- December 12, 2025: Judge Christopher R. Cooper grants summary judgment for HHS, upholding the findings and debarment.
- Through August 2026: The three-year debarment period runs its course, absent further appeal.
Frequently asked questions
Is the Frech v. HHS case still open?
The district-court challenge was resolved by the December 12, 2025 summary judgment in HHS’s favor, which upheld both the misconduct findings and the debarment. This account reflects the record as of that ruling; readers should check court dockets directly for any subsequent appeal.
What exactly did ORI find?
ORI found that Frech falsified and/or fabricated eight western blot and autoradiogram images across three PHS-funded publications connected to her work at the University of Utah, in violation of the federal research-misconduct definition covering fabrication, falsification, and plagiarism.
How long does the debarment last?
Three years, effective August 21, 2023 and running through August 2026, during which Frech is excluded from covered federal transactions and from PHS advisory, peer-review, and consulting roles.
Why does a federal court’s review of an ORI debarment matter beyond this one case?
Judicial review of ORI actions is uncommon, so a reasoned summary-judgment opinion gives institutions, respondents, and counsel one of the few available benchmarks for how a court weighs the agency’s administrative record and process — including how it treats lengthy investigation timelines — under the arbitrary-and-capricious standard.
Sources: U.S. District Court for the District of Columbia summary judgment order, Frech v. HHS, No. 23-2530 (D.D.C. Dec. 12, 2025); ORI case summary for Ivana Frech (ori.hhs.gov); Retraction Watch, “Court tosses out researcher’s bid to overturn funding ban,” Dec. 23, 2025.
